Nordic Bioscience’s Unique Biomarker PRO-C3 Gets Green Light for Further Study in Cancer from US FDA in Formal Letter of Support

Nordic Bioscience, a leading biomarker company, today announced that the company’s PRO-C3 biomarker assay has received a Letter of Support from the FDA. This letter acknowledges and supports further study of the PRO-C3 biomarker assay as a prognostic biomarker in tumor fibrosis studies.